The FDA decision on Pfizer Inc.’s (PFE) Abrocitinib, proposed for the treatment of moderate to severe atopic dermatitis in patients 12 and older, is expected to be announced in April.Abrocitinib is an oral, once-daily, small molecule that selectively inhibits a protein Janus kinase (JAK) 1. Inhibition of JAK1 is said to reduce inflammation.In clinical trials, Abrocitinib, has demonstrated significant symptom improvements, say, skin clearance, disease extent and severity, and itch, compared to placebo. In one of the trials, Abrocitinib even proved to be superior to Sanofi /Regeneron's approved biologic medicine Dupixent in treating moderate to severe atopic dermatitis.If approved, Abrocitinib could generate peak sales of over $3 billion, according to the company.PFE closed Friday’s (Mar.26, 2021) trading at $36.25, up 1.63%.